A controlled crossover study of triiodothyronine in autistic children.
A placebo-controlled crossover study of behavioral effects of triiodothyronine (T3) was conducted in 30 young clinically euthyroid autistic children. Multiple independent raters and multiple rating scales were used. Except for a few symptoms that were reduced on T3, the drug did not differ from placebo. Time itself accounted for most of the improvement in the whole sample. As a group, the lower IQ children responded to T3. The individual children who were responders could not be defined by any parameter.
D001321:Autistic Disorder / Q000188:drug therapy* / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002648:Child; D002652:Child Behavior / Q000187:drug effects; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007360:Intelligence; D008297:Male; D011569:Psychiatric Status Rating Scales; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D014284:Triiodothyronine; D013974:Thyroxine